Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 14/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.36 |
| ▸ | PDE1A | P54750 | 2/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7905610 | 0.94 | PDE9A (0.44) | PDE9APDE5APDE1BPDE1APDE1C | |
| SCHEMBL12044656 | 0.92 | PDE9A (0.46) | PDE9APDE5APDE1BPDE1APDE1C | |
| SCHEMBL10186206 | 0.91 | PDE9A (0.44) | PDE9APDE5AL3MBTL1 | |
| SCHEMBL7905664 | 0.91 | PDE9A (0.42) | PDE9APDE5APDE1BL3MBTL1 | |
| SCHEMBL7908597 | 0.90 | PDE9A (0.42) | PDE9APDE5A | |
| SCHEMBL12044199 | 0.90 | PDE9A (0.41) | PDE9APDE5APDE1BL3MBTL1 | |
| SCHEMBL7896957 | 0.89 | PDE9A (0.41) | PDE9APDE5A | |
| SCHEMBL7900285 | 0.89 | PDE9A (0.44) | PDE9APDE5A | |
| SCHEMBL12044822 | 0.89 | PDE9A (0.44) | PDE9APDE5APDE1BPDE1APDE1C | |
| SCHEMBL1723938 | 0.88 | PDE9A (0.43) | PDE9APDE5APDE1BPDE1APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085134-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085134-A1 | QUINOXALINE COMPOUND | PDE9A, PDE2A, PDE3A | PDE9A 1/4885PDE5A 4/4885PDE1B 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.